A carregar...
Immune checkpoint inhibitors in challenging populations
Immune checkpoint inhibitors, including those targeting the PD-1/PD-L1 and CTLA-4 pathways, are revolutionizing cancer therapeutics. Both activity and toxicities largely stem from unleashing tumor- or host-specific cytotoxic T cells. Many patients seen in routine clinical practice did not qualify fo...
Na minha lista:
| Publicado no: | Cancer |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5445005/ https://ncbi.nlm.nih.gov/pubmed/28241095 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30642 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|